Following its success in the burgeoning area of CAR-T therapies, Novartis is looking to strengthen its cell and gene manufacturing capabilities by offering t
Joe Jimenez is to step down after eight years as Novartis chief executive, and will be leaving on a high after last week’s first-in-class CAR-T approval.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.